



# **NUAK2 Antibody (N-term) Blocking Peptide**

Synthetic peptide Catalog # BP7158a

## **Specification**

NUAK2 Antibody (N-term) Blocking Peptide - Product Information

Primary Accession <u>Q9H093</u>

NUAK2 Antibody (N-term) Blocking Peptide - Additional Information

**Gene ID 81788** 

#### **Other Names**

NUAK family SNF1-like kinase 2, Omphalocele kinase 2, SNF1/AMP kinase-related kinase, SNARK, NUAK2 {ECO:0000312|EMBL:AAH173061}, OMPHK2, SNARK

#### **Target/Specificity**

The synthetic peptide sequence used to generate the antibody <a href=/product/pr oducts/AP7158a>AP7158a</a> was selected from the N-term region of human NUAK2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

## **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

## **Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.


NUAK2 Antibody (N-term) Blocking Peptide - Protein Information

# NUAK2 Antibody (N-term) Blocking Peptide - Background

Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells.

# NUAK2 Antibody (N-term) Blocking Peptide - References

Lefebvre, D.L., et al., Biochem. J. 355 (Pt 2), 297-305 (2001) (): ().





Name NUAK2 {ECO:0000312|EMBL:AAH17306.1}

Synonyms OMPHK2, SNARK

## **Function**

Stress-activated kinase involved in tolerance to glucose starvation. Induces cell-cell detachment by increasing F-actin conversion to G-actin. Expression is induced by CD95 or TNF-alpha, via NF-kappa-B. Protects cells from CD95-mediated apoptosis and is required for the increased motility and invasiveness of CD95-activated tumor cells. Able to phosphorylate 'Ser-464' of LATS1.

# NUAK2 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides